Compare Allegion PLC (ALLE) vs BridgeBio Pharma Inc (BBIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Allegion PLC vs BridgeBio Pharma Inc — how do they compare? Allegion PLC trades at $168.66 (market cap $14.32B), while BridgeBio Pharma Inc trades at $83.86 (market cap $16.36B). The key difference: Allegion PLC and BridgeBio Pharma Inc are close in size by market cap, and Allegion PLC pays a 1.26% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| ALLE | BBIO | |
|---|---|---|
Market Cap | $14.32B | $16.36B |
Sector | Industrials | Health |
52-Week High | $179.77 | $90.17 |
52-Week Low | $125.65 | $47.29 |
Enterprise Value | $16.03B | $18.14B |
Dividend Yield | 1.26% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Allegion PLC
Allegion is a global security products company with a portfolio of leading brands, such as Schlage, von Duprin, and LCN. The Ireland-domiciled company was created via a spinoff transaction from Ingersoll-Rand in December 2013. In fiscal 2021, Allegion generated 68% of sales in the United States. The company mainly competes with Swedish-based Assa Abloy AB and Switzerland-based Dormakaba.
Read more on ALLE →About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →
